Neuralgia Treatment Market Report 2026

Neuralgia Treatment Market Overview

• Neuralgia Treatment market size has reached to $2.43 billion in 2025 • Expected to grow to $3.38 billion in 2030 at a compound annual growth rate (CAGR) of 7% • Growth Driver: Growing Prevalence Of Chronic Diseases, Including Diabetes, Fuels Growth In The Neuralgia Treatment Market • Market Trend: Innovative Products Drive Market Advancements In The Neuralgia Treatment Industry • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Neuralgia Treatment Market?

Neuralgia treatment refers to treating a medical condition characterized by chronic pain that affects the nerves and can be caused by injury, infection, or underlying medical conditions. Neuralgia treatment is used to manage symptoms, slow the progression of the Neuralgia and prevent complications. The main types of neuralgia treatments included are drug-based and surgeries. Drug-based treatment refers to the treatment through the use of drugs or medications to manage, alleviate, or cure various medical conditions and diseases. Various types of indications are involved, such as diabetic neuropathy, intercostal neuralgia, occipital neuralgia, peripheral neuralgia and postherpetic neuralgia. It is sold through several distribution channels, including drug stores, hospital pharmacies, online pharmacies and retail pharmacies and is used for various end-uses, such as hospitals and clinics, ambulatory surgery centers and others.

What Is The Neuralgia Treatment Market Growth Forecast?

The neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $3.38 billion in 2030 at a compound annual growth rate (CAGR) of 7.0%. The growth in the forecast period can be attributed to growth in minimally invasive surgical pain treatments, rising demand for spinal cord stimulation devices, increasing use of targeted topical therapies, expansion of telemedicine-based neuralgia care, development of next-generation non-opioid pain medications. Major trends in the forecast period include growing use of drug-based neuralgia management, increasing adoption of nerve block and decompression procedures, rising demand for topical pain relief therapies, expansion of spinal cord stimulation for chronic neuralgia, increasing focus on early diagnosis and long-term pain management.

Global Neuralgia Treatment Market Segmentation

1) By Treatment: Drug-Based, Surgeries 2) By Indication: Diabetic Neuropathy, Intercostal Neuralgia, Occipital Neuralgia, Peripheral Neuralgia, Postherpetic Neuralgia 3) By Distribution channel: Drug Stores, Hospital Pharmacies, Online Pharmacies, Retail Pharmacies 4) By End-User: Hospitals And Clinics, Ambulatory Surgery Centers, Other End-Users Subsegments: 1) By Drug-Based: Anticonvulsants, Antidepressants, Opioids, Topical Treatments, Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) 2) By Surgeries: Nerve Block Procedures, Decompression Surgery, Neurectomy, Spinal Cord Stimulation

What Is The Driver Of The Neuralgia Treatment Market?

The rising prevalence of chronic diseases, such as diabetes, is expected to propel the growth of the neuralgia treatment market going forward. Chronic diseases are problems that last a year or longer, necessitating continuing medical care, restricting everyday activities, or both. Diabetes is a long-term metabolic condition characterized by high blood glucose, also called blood sugar. Neuralgia treatment can treat diabetic neuropathy, the nerve damage that can occur in people with diabetes. For instance, in March 2024, according to the Office for Health Improvement and Disparities, a UK-based government department, between March 2022 and March 2023, the percentage of individuals with type 1 diabetes receiving all eight recommended care processes increased by 22%, and for type 2 diabetes, it increased by 21%, while the percentage achieving target HbA1c levels rose to 37.9%, the highest value ever reported by the National Diabetes Audit (NDA). Therefore, the rising prevalence of chronic diseases, such as diabetes, is driving the growth of the neuralgia treatment industry.

Key Players In The Global Neuralgia Treatment Market

Major companies operating in the neuralgia treatment market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bayer AG, Novartis AG, Bristol-Myers Squibb Company, AstraZeneca plc, Abbott Laboratories, GlaxoSmithKline plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Mylan N.V., Biogen Inc., Boehringer Ingelheim International GmbH, Sun Pharmaceutical Industries Limited, Purdue Pharma, Dr. Reddy's Laboratories, Cipla Limited, Hikma Pharmaceuticals plc, Zydus Lifesciences Ltd., Lupin Limited, Mallinckrodt Pharmaceuticals, Glenmark Pharmaceuticals

Global Neuralgia Treatment Market Trends and Insights

Major companies operating in the neuralgia treatment market are focusing on developing advanced solutions, such as peripheral nerve-targeted delivery systems, to improve therapeutic precision, reduce chronic neuropathic pain, and enhance long-term patient outcomes. Peripheral nerve-targeted delivery systems refer to specialized therapeutic platforms that concentrate analgesic or neuromodulatory agents directly at affected nerves, enabling more accurate modulation of pain signals while minimizing systemic exposure. For instance, in April 2023, in India, GlaxoSmithKline Pharmaceuticals Ltd., an India-based pharmaceutical company, launched Shingrix, the world's first non-live and recombinant subunit vaccine. This vaccine is designed to prevent shingles and post-herpetic neuralgia in adults aged 50 years and older and is administered intramuscularly in two doses. Shingrix combines the antigen glycoprotein E with the adjuvant system AS01B to produce a potent and long-lasting immunological response that can help counteract the immune system's deterioration with age. Clinical trials have shown that it is 97% effective in preventing shingles in adults. It also effectively prevents post-herpetic neuralgia, a painful complication of shingles.

What Are Latest Mergers And Acquisitions In The Neuralgia Treatment Market?

In September 2025, Semnur Pharmaceuticals, Inc., a US-based developer of non-opioid, targeted pain management therapeutics, completed a merger with Denali Capital Acquisition Corp. for an undisclosed amount. With this merger, Semnur aims to transition into a publicly traded company and accelerate the expansion of its non-opioid pain management programs across acute, chronic, and neuropathic pain indications. Denali Capital Acquisition Corp. is a US-based special purpose acquisition company (SPAC).

Regional Outlook

North America was the largest region in the neuralgia treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Neuralgia Treatment Market?

The neuralgia treatment market consists of revenues earned by entities by providing blood tests, magnetic resonance imaging (MRI), nerve conduction velocity tests, physical therapies and alternative therapies. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuralgia treatment market also includes sales of anticonvulsant medications, pain relievers, antidepressants and antiseizure medications. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Neuralgia Treatment Market Report 2026?

The neuralgia treatment market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the neuralgia treatment industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.